Sarepta Therapeutics Inc. (SRPT) announced Wednesday morning that results at 84 weeks from its Phase IIb open-label extension study of eteplirsen, in patients with Duchenne muscular dystrophy, showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test.
Sarepta Therapeutics gapped open sharply higher Wednesday and is now up 1.71 at $39.86. The stock is now challenging resistance, trading at nearly a 3-week high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.